Analysis of FHIT Gene Methylation in Egyptian Breast Cancer Women: Association with Clinicopathological Features

  • Zaki, Seham Mahrous (Clinical Pathology, Faculty of Medicine, Zagazig University Hospitals) ;
  • Abdel-Azeez, Hala A. (Clinical Pathology, Faculty of Medicine, Zagazig University Hospitals) ;
  • El Nagar, Mona Roshdy (Pathology, Faculty of Medicine, Zagazig University Hospitals) ;
  • Metwally, Khaled Abdel-Aziz (Surgery, Faculty of Medicine, Zagazig University Hospitals) ;
  • Ahmed, Marwa M. Samir S. (Clinical Pathology, Faculty of Medicine, Zagazig University Hospitals)
  • Published : 2015.03.04


Background: Fragile histidine triad (FHIT) gene is a tumor suppressor gene which involved in breast cancer pathogenesis. Epigenetics alterations in FHIT contributes to tumorigenesis of breast cancer. Objective: Our objective was to study FHIT promoter region hypermethylation in Egyptian breast cancer patients and its association with clinicopathological features. Materials and Methods: Methylation-specific polymerase chain reaction was performed to study the hypermethylation of FHIT promoter region in 20 benign breast tissues and 30 breast cancer tissues. Results: The frequency of hypermethylation of FHIT promoter region was significantly increased in breast cancer patients compared to bengin breast disease patients. The Odd's ratio (95%CI) of development of breast cancer in individuals with FHIT promoter hypermethylation (MM) was 11.0 (1.22-250.8). There were also significant associations between FHIT promoter hypermethylation and estrogen, progesterone receptors negativity, tumor stage and nodal involvment in breast cancer pateints. Conclusions: Our results support an association between FHIT promotor hypermethylation and development of breast cancer in Egyptian breast cancer patients. FHIT promoter hypermethylation is associated with some poor prognostic features of breast cancer.


  1. Arun B, Kilic G, Yen C, et al (2005). Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev, 14, 1681-5.
  2. Bhikoo R, Srinivasa S, Yu TC, et al (2011). Systematic review of breast cancer biology in developing countries (part 1): Africa, the Middle East, Eastern Europe, Mexico, the Caribbean and South America. Cancers, 3, 2358-81.
  3. Campan M, Weisenberger DJ, and Laird PW (2006). DNA methylation profiles of female steroid hormone-driven human malignancies. Curr Top Microbiol Immunol, 310, 141-78.
  4. Chen X, Li P, Yang Z, Mo WN (2013). Expression of fragile histidine triad (FHIT) and WW-domain oxidoreductase gene (WWOX) in nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 14, 165-71.
  5. Choi CH, Lee KM, Choi JJ, et al (2007). Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett, 255, 26-33.
  6. Esteller M (2003). Relevance of DNA methylation in the management of cancer. Lancet Oncol, 4, 351-8.
  7. Frommer M, Mcdonld LE, Millar DS, et al (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA, 89, 1827-31.
  8. Gatalica Z, Lele SM, Rampy BA, and Norris BA (2000). The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer, 88, 1378-83.<1378::AID-CNCR15>3.0.CO;2-I
  9. Golebiowski F, Szulc A, Szutowicz A, Pawelczyk T (2004). Ubc9-induced V inhibition of diadenosine triphosphate hydrolase activity of the putative; tumor suppressor protein FHIT. Arch Biochem Biophy, 428, 160-4.
  10. Han Y, Zhang Z, Zhang GJ, et al (2011). Aberrant FHIT expression is linked to bladder carcinogenesis and apoptosis. Asian Pac J Cancer Prev, 12, 2915-20.
  11. Haroun RA, Zakhary NI, Mohamed MR, et al (2014). Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients. Asian Pac J Cancer Prev, 15, 4281-7.
  12. IIiopoulos D, Guler G, Han SY, et al (2006). Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett, 232, 27-36
  13. Jing F, Yuping W, Yong C, et al (2010). CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumor Biol, 31, 321-31.
  14. Jeong YJ, Jeong HY, Lee SM, et al (2013). Promotor methylation status of FHIT gene and Fhit expression: Association with HER2/neu status in breast cancer patients. Oncol Rep, 30, 2270-8.
  15. Kim JS, Kim JW, Han J, et al (2006). Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res, 15, 4049-54.
  16. Laird PW (2003). The power and the promise of DNA methylation markers. Nat Rev Cancer, 3, 253-66.
  17. Li W, Deng J, Tang JX (2014). Combined effects methylation of FHIT, RASSF1A and $RAR{\beta}$ genes on non-small cell lung cancer in the Chinese population. Asian Pac J Cancer Prev, 15, 5233-7.
  18. Li S, Rong M, Iacopetta B (2006). DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett, 237, 272-80.
  19. Naqvi RA, Hussain A, Raish M, et al (2008). Specific 5'CpG island methylation signatures of FHIT and p16 genes and their potential diagnostic relevance in Indian breast cancer patients. DNA Cell Biol, 27, 517-25.
  20. Patel A, Groopman JD, Umar A (2003). DNA methylation as a cancer-specific biomarker: from molecules to populations. Ann NY Acad Sci, 98, 286-97.
  21. Raish M, Dhillon VS, Ahmad A, et al (2009). Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Transl Oncol, 4, 264-70.
  22. Roa JC, Anabalon L, Tapia O, et al (2004). Promoter methylation profile in breast cancer. Rev Med Chile, 13, 1069-77.
  23. Salem AAS, Salem MA, Abbass H (2010). Breast cancer: surgery at the South Egypt cancer institute. Cancers, 2, 1771-8.
  24. Singletary SE, Connolly JL (2006). Breast cancer staging:working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin, 56, 37-47.
  25. Syeed N, Husain SA, Sameer AS, Chowdhri NA, Siddiqi MA (2011). Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir. Mutat Res, 707, 1-8.
  26. Tan S, Sun C, Wei X, et al (2013). Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood. Exp Lung Res, 39, 182-90.
  27. Tao MH, Shields PG, Nie J, et al (2009). DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat, 114, 559-68.
  28. Terry G, Ho L, Londesborough P, et al (2007). The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. Br J Cancer, 96, 110-7.
  29. Wali A (2010). FHIT: doubts are clear now mini-review. Sci World J, 10, 1142-51.
  30. Yang Q, Yoshimura G, Suzuma T, et al (2001). Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res, 7, 3869-73.
  31. Yang Q, Mori I, Shan L, et al (2001). Biallelic inactivation of retinoic acid receptor 2 gene by epigenetic change in breast cancer. Am J Pathol, 158, 299-303.
  32. Yang Q, Yoshimura G, Sakurai T, Kakudo K (2002). The fragile histidine triad gene and breast cancer. Med Sci Monit, 8, 140-4.
  33. Zochbauer-Muller S, Fong KM, Maitra A, et al (2001). 5'CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res, 61, 3581-5.
  34. Zheng S, Ma X, Zhang L, et al (2004). Hypermethylation of the 5_CpG Island of the FHIT Gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. Cancer Res, 64, 2000-6.

Cited by

  1. DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study vol.11, pp.9, 2016,
  2. DNA methylation alterations induced by transient exposure of MCF-7 cells to maghemite nanoparticles vol.12, pp.23, 2017,
  3. FHIT promoter DNA methylation and expression analysis in childhood acute lymphoblastic leukemia vol.14, pp.4, 2017,
  4. gene alterations play a role in human solid tumors? vol.14, pp.5, 2018,